Furthermore, knockdown of EphB4 has been reported to suppress the cell proliferation of lung adenocarcinoma cell lines [39], and knockdown of EphA2 has been reported to improve gefitinib sensitivity in gefitinib-resistant lung adenocarcinoma cell lines [40]. Here, EPHB4 is linked to lung adenocarcinoma.